Journal of Medicinal Chemistry p. 1613 - 1633 (2016)
Update date:2022-08-15
Topics:
Reddy, Damodara N.
Ballante, Flavio
Chuang, Timothy
Pirolli, Adele
Marrocco, Biagina
Marshall, Garland R.
Selective inhibition of KDAC isoforms while maintaining potency remains a challenge. Using the largazole macrocyclic depsipeptide structure as a starting point for developing new KDACIs with increased selectivity, a combination of four different simplified largazole analogue (SLA) scaffolds with diverse zinc-binding groups (for a total of 60 compounds) were designed, synthesized, and evaluated against class I KDACs 1, 3, and 8, and class II KDAC6. Experimental evidence as well as molecular docking poses converged to establish the cyclic tetrapeptides (CTPs) as the primary determinant of both potency and selectivity by influencing the correct alignment of the zinc-binding group in the KDAC active site, providing a further basis for developing new KDACIs of higher isoform selectivity and potency.
View MoreContact:
Address:
Shanghai Puda Chemical Co.,Ltd
Contact:+86+571+56565965
Address:10F Haiyue Building,Danfeng Road,Binjiang District,Hangzhou,China
Qingdao Kingway Pharmtech Co., Ltd.
Contact:86-532-87118899
Address:No. 88, Middle Haixi Road, Jiaonan City, Qingdao, China
website:http://www.mascot-ie.com
Contact:86-519-85010339
Address:B-802,XingBei Building,391#,Tongjiang Middle Road New District,Changzhou,JS,China
Contact:886 2 2541 0022
Address:8 Fl., No. 11, Sec. 1, Chung Shan North Rd., Taipei, Taiwan R.O.C.
Doi:10.1246/bcsj.65.3288
(1992)Doi:10.1021/jm00054a005
(1993)Doi:10.3390/ijms19103050
(2018)Doi:10.1016/S0040-4039(99)00389-5
(1999)Doi:10.1016/S0957-4166(97)00614-9
(1998)Doi:10.1002/chem.201600229
(2016)